Screening and treatment of localized prostate cancer decreases mortality: First analysis of the first prospective and randomized study on prostate cancer screening

References

• Landis S H, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8–31
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Bélanger A, Cusan Lacourci L., Ére Y, Monfette G, et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982; 5: 267–75
   PubMed Web of Science ®Google Scholar
• Crawford E D, Eisenberger M A, McLeod D G, Spaulding J T, Benson R, Dorr F A, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–24
   PubMed Web of Science ®Google Scholar
• Denis L, Carnelro de Moura J L, Bono A, Sylvester R, Whelan R, Newling D, et al. Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993; 42: 119–29
   PubMed Web of Science ®Google Scholar
• Janknegt R A, Abbou C C, Bartoletti R, Bemstein-Hahn L, Bracken B, Brisset J M, et al. Orchiectomy and Nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational doubleblind randomized trial. J Urol 1993; 149: 77–83
   PubMed Web of Science ®Google Scholar
• Caubet J F, Tosteson T D, Dong E W, Naylon E M, Whiting G W, Ernstoff M S, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997; 49: 71–8
   PubMed Web of Science ®Google Scholar
• Dijkman G A, Janknegt R A, Dereijke T M, Debruyne F MJ. Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization. J Urol 1997; 158: 160–3
   PubMed Web of Science ®Google Scholar
• Labrie F., De Vita V T, Hellman S, Rosenberg S A. Cancer: Principle and Practice of Oncology. Lippincott-Raven, Philadelphia 1999; 13: 1–9
   Google Scholar
• Labrie F. Combined androgen blockade and treatment of localized prostate cancer: a real hope when approaching the year 2000. Endocrine-Related Cancer 1998; 5: 341–51
   Google Scholar
• Labrie F, Cusan L, Gomez J L, Diamond P, Bélanger A. Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol Urol 1997; 1: 253–63
   Google Scholar
• Hoeksema M J, Law C. Cancer mortality rates fall: a turning point for the nation. J Natl Cancer Inst 1996; 88: 1706–7
   PubMed Web of Science ®Google Scholar
• Krongrad A, Lai H, Lamm S H, Lai S. Mortality in prostate cancer. J Urol 1996; 156: 1084–91
   PubMedGoogle Scholar
• Killian C S, Emrich L J, Vargas F P, Yang N, Wang M C, Priore R L, et al. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J Natl Cancer Inst 1986; 76: 179–85
   PubMedGoogle Scholar
• Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez J L, et al. Serum prostatic specific antigen (PSA) as prescreening test for prostate cancer. J Urol 1992; 147: 846–51
   PubMed Web of Science ®Google Scholar
• Labrie F, Candas B, Cusan L, Gomez J L, Diamond P, Suburu R, et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996; 47: 212–17
   PubMedGoogle Scholar
• Lee F, Torp-Pedersen S T, Siders D B, Littrup P J, McLeary RD. Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology 1989; 170: 609–15
   PubMed Web of Science ®Google Scholar
• Hanks G E, Asbell S O, Krall J M, Perez C A, Doggett S, Rubin P, et al. Outcome for lymph node dissection negative T-1b, T-2 (A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77–06. Int J Radiat Oncol Biol Phys 1991; 21: 1099–103
   PubMedGoogle Scholar
• Cooner W H, Mosley B R, Rutherford CL, Jr, Beard J H, Pond H S, Terry W J, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-specific antigen. Urology 1990; 143: 1146–54
   Google Scholar
• Labrie F, Cusan L, Gomez J L, Diamond P, Suburu R, Lemay M, et al. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with Flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994; 44: 29–37
   Web of Science ®Google Scholar
• Laverdiere J, Gomez J L, Cusan L, Suburu R, Diamond P, Lemay M, et al. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 247–52
   PubMed Web of Science ®Google Scholar
• Pilepich M V, Krall J M, Al-Saffaf M, John M J, Dogger R L, Sause W T, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616–23
   PubMed Web of Science ®Google Scholar
• Bolla M, Gonzalez D, Warde P, Dubois J B, Mirimanoff R O, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295–300
   PubMed Web of Science ®Google Scholar
• Blasko J, Ragde H, Luse R, et al. Should brachy-therapy be considered a therapeutic option in localized prostate cancer?. Urol Clin North Am 1996; 23: 633–49
   PubMedGoogle Scholar
• Labrie F, Candas B, Dupont A, Cusan L, Gomez J L, Suburu R E, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83–91
   PubMedGoogle Scholar
• Lee F, Littrup P J, Loft-Christensen L, Kelly BS, Jr, McHugh T A, Siders D B, et al. Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer. Cancer 1992; 70((Suppl))211–20
   PubMedGoogle Scholar
• Littrup P J, Williams C R, Egglin T K, Kane RA. Determination of prostate volume by transrectal US for cancer screening. II. Clinical utility of transrectal accuracy of in vivo and in vitro techniques. Radiology 1991; 179: 45–53
   Google Scholar
• Hodge K K, McNeal J E, Terris M F, Stamey T A. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71–5
   PubMed Web of Science ®Google Scholar
• Littrup P J, Goodman A C, Mettlin CJ. The benefit and cost of prostate cancer early detection. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. CA Cancer J Clin 1993; 43: 143–9
   Google Scholar
• Schröder F H, van der Maas P, Beemsterboer P, Kruger A B, Hoedemaeker R, Rietbergen J, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 1998; 90: 1817–23
   PubMedGoogle Scholar
• Hulka BS. Cancer screening. Degrees of proof and practical application. Cancer 1988; 62: 776–80
   Google Scholar
• Labrie F, Dupont A, Suburu R, Cusan L, Gomez J L, Koutsilieris M, et al. Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostatic-specific antigen. Clin Invest Med 1993; 16: 425–39
   PubMed Web of Science ®Google Scholar
• Narod S, Dupont A, Cusan L, Diamond P, Gomez J L, Suburu R E, et al. The impact of family history on early detection of prostate cancer. Nature Med 1995; 1: 99–101
   PubMed Web of Science ®Google Scholar
• Sun S, Narod S, Aprikian A, Ghadirian P, Labrie F. Androgen receptor and familial prostate cancer. Nature Med 1995; 1: 848–9
   PubMedGoogle Scholar
• Kolata G. Prostate cancer consensus hampered by lack of data. Science 1987; 236: 1626–7
   PubMed Web of Science ®Google Scholar
• Pilepich M V, Caplan R, Byhardt R W, Lawton C A, Gallagher M J, Mesic J B, et al. Phase III trial of androgen suppression using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85–31. J Clin Oncol 1997; 15: 1013–21
   PubMed Web of Science ®Google Scholar
• Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993; 72: 3888–95
   PubMed Web of Science ®Google Scholar
• van den Ouden D, Tribukait B, Blom J H, Fossa S D, Kurth K H, ten Kate F J, et al. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1993; 150: 400–6
   PubMedGoogle Scholar
• Zagars G K, Sands M E, Pollack A, von Eschenbach AC. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome. J Urol 1994; 151: 1330–3
   PubMedGoogle Scholar
• Kramolowski EV. The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 1988; 139: 1242–4
   PubMedGoogle Scholar
• Medical Research Council Trial. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997; 79: 235–46
   PubMedGoogle Scholar
• Brown M L, Fintor L, Newman-Horm PA. The economic burden of cancer. J Natl Cancer Inst 1993; 85: 351–3
   Google Scholar
• Labrie F, Dupont A, Cusan L, Gomez J L, Diamond P, Koutsilieris M, et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 1993; 16: 499–509
   PubMed Web of Science ®Google Scholar
• Littrup P J, Kane R A, Mettlin C J, Murphy G P, Lee F, Toi A, et al. Cost-effective prostate-cancer detection. Reduction of low-field biopsies. Cancer 1994; 74: 3146–58
   PubMed Web of Science ®Google Scholar
• Aus G, Hugosson J, Norlén L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995; 154: 460–5
   PubMed Web of Science ®Google Scholar
• Labrie F. Intracrinology and cancer therapy. Science Watch 1994; 5: 3–8
   Google Scholar
• Labrie F, Cusan L, Gomez J L, Diamond P, Candas B. Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. J Clin Endocrinol Metab 1995; 80: 2002–13
   PubMedGoogle Scholar
• Jacobs SC. Spread of prostatic cancer to bone. Urology 1983; 21: 337–44
   PubMed Web of Science ®Google Scholar
• Gleave M E, Hsieh J T, von Eschenbach A C, Chung LW. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 1992; 147: 1151–9
   PubMed Web of Science ®Google Scholar
• Chackal-Roy M, Niemeyer C, Moore M, Zetter BR. Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J Clin Invest 1989; 84: 43–50
   PubMed Web of Science ®Google Scholar